Abstract
The Use of Fedratinib (FEDR) for Myelofibrosis (MF) As a Potential Bridge to Hematopoietic Stem Cell Transplantation (HSCT) after Ruxolitinib (RUX) Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptoms, and Hematologic Response
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
